Project

SAKK 21/18 Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A mul-ticenter, randomized phase III trial

Ongoing - recruitment active · 2019 until 2026

Hasler-Strub Ursula